Company: BGLC
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001477932-25-008343
Chunk: 8

Company: BioNexus Gene Lab Corp
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 8
---
ables  (161,860)  150,638 Trade and other payables  (1,227,454)  (257,832)Advance payment from customer  (84,615)  22,834 Operating lease liabilities  (26,811)  (24,342)Tax (liabilities)/recoverable  (19,473)  36,847 Net cash used in operating activities  (2,799,444)  (2,312,463)         Cash flows from investing activities:        Acquisition of investments in equity securities  (9,064)  (486,170)Dividend income  21,752   59,653 Change in fixed deposits placed with original maturities more than three months  (47,099)  (60,244)Purchase of plant and equipment  (35,994)  (222,967)Proceeds from disposal of investments in equity securities  1,020,873   494,741 Proceeds from settlement of supplier contract dispute  -   78,787 Net cash generated from/(used in) investing activities  950,468   (136,200)         Cash flows from financing activities:        Advances from Directors  32,802   5,362 Share-base compensation  -   141,000 Cash paid for fractional shares in reverse stock split  (505)  - Net cash generated from financing activities  32,297   146,362          Foreign currency translation adjustment  286,805   449,940 NET CHANGE IN CASH AND CASH EQUIVALENTS  (1,529,874)  (1,852,361)CASH AND CASH EQUIVALENTS, BEGINNING OF FINANCIAL PERIOD  2,886,966   4,517,710          CASH AND CASH EQUIVALENTS, END OF FINANCIAL PERIOD $1,357,092  $2,665,349          CASH AND CASH EQUIVALENTS INFORMATION:        Fixed deposits placed with financial institutions with original maturities of three months or less $203,971  $603,633 Cash and bank balances  1,153,121